Abstracts tagged "SLE"

Abstract Number: 1242 • 2017 ACR/ARHP Annual Meeting
Impact of Social Support and Illness Perception on the Transition of Pediatric SLE Patients to Adult Care
Mary Beth Son¹, David Zurakowski², David J. Kreps³, Siobhan Case⁴ and Karen H. Costenbader³, ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Departments of Anesthesia and Surgery, Boston Children’s Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Boston Children's Hospital, Boston, MA
Background/Purpose : We surveyed adult patients with a history of pediatric systemic lupus erythematosus (pSLE) regarding their process of transition from pediatric to adult care…
Abstract Number: 1668 • 2017 ACR/ARHP Annual Meeting
Identification of a Serum Measure of Lupus Nephritis Activity That Detects Molecular Pathways and Mechanisms Implicated in Renal Damage
Mikhail Olferiev¹, Dina Greenman², David Fernandez¹, Kerry Merritt¹, Kyriakos A. Kirou¹ and Mary K. Crow³, ¹Hospital for Special Surgery, New York, NY, ²Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Up to 60% of SLE patients develop renal involvement, and renal injury is an important predictor of mortality in patients with SLE. Kidney biopsy…
Abstract Number: 2576 • 2017 ACR/ARHP Annual Meeting
Caspase 8 in Dendritic Cells Suppresses IRF5 Activation through Endosomal TLR Signaling to Prevent SLE-like Disease
FuNien Tsai¹, Harris Perlman² and Carla Cuda², ¹Medicine-Rheumatology, Northwestern University-Feinberg School of Medicine, Chicago, IL, ²Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Previous studies implicate dendritic cells (DCs) in the pathogenesis of systemic lupus erythematosus (SLE), yet the mechanisms underlying this involvement are not yet clear.…
Abstract Number: 2707 • 2017 ACR/ARHP Annual Meeting
Estrogen Downregulates the Expression of Serine Arginine Splicing Factor 1 (SRSF1) in Human T Lymphocytes
Elena N. Cravens¹, Takayuki Katsuyama¹, Andrew R. Gillooly², George C. Tsokos¹ and Vaishali R. Moulton¹, ¹Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Medicine/ Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with multifactorial etiopathogenesis that primarily afflicts women in the childbearing years. Hormones especially estrogen are…
Abstract Number: 331 • 2017 ACR/ARHP Annual Meeting
Case Series: Comparison of Repository Corticotropin Injection (H.P. Acthar Gel) Versus Glucocorticoids on Bone Density in SLE Patients
Anny T. Wu¹ and Joshua June², ¹Rheumatology, Franciscan Alliance, Munster, IN, ²3394 E Jolly Rd Ste C, Great Lakes Center of Rheumatology, Lansing, MI
Background/Purpose: Repository Corticotropin Injection (RCI) is an adrenocorticotropin hormone in 16% gelatin with a prolonged release after intramuscular (IM) or subcutaneous injection. Adverse effects of…
Abstract Number: 1269 • 2017 ACR/ARHP Annual Meeting
Investigating Time Trends in Incident Pediatric Lupus across Ethnic Groups in Toronto, Canada—a Large, Multiethnic Metropolitan Area
Laura Y Feldman¹, Patrick Brown², Linda T Hiraki^1,3 and Earl Silverman³, ¹Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ²Department of Statistical Sciences, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Lupus incidence rates are known to differ by ethnicity among children and adults, with African ancestry as a risk factor for incident lupus, compared…
Abstract Number: 1671 • 2017 ACR/ARHP Annual Meeting
Complement C4 Gene Copy Number Variations Bestow Large Ranges of Serum C4 Protein Levels in Chinese Patients with Systemic Lupus Erythematosus (SLE) and Contribute to Organ and Cardiovascular Damages over Time
Chi Chiu Mok¹, Emily King², Bi Zhou³, Gakit Yu⁴, Yee Ling Wu⁵ and CHACK-YUNG Yu⁶, ¹Rheumatology, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Pediatrics, Nationwide Children's Hospital, Columbus, OH, ³Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, ⁴Center for Molecular and Human Genetics, Nationwide Children's Hospital, Columbus, OH, ⁵Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital, Columbus, OH, ⁶Pediatrics, Ohio State Univ, Columbus, OH
Background/Purpose: Human SLE is characterized by fluctuating serum levels of complement proteins. There are frequent copy number variations (CNVs) of complement C4A and C4B genes…
Abstract Number: 2581 • 2017 ACR/ARHP Annual Meeting
Safety of Hydroxychloroquine Withdrawal in Older Adults with Systemic Lupus Erythematosus
Anna Zezon¹, Peter M. Izmirly², Nicole Bornkamp³, Chung-E Tseng⁴, H. Michael Belmont³, Anca Askanase⁵, Jane E. Salmon⁶, Michael Lockshin⁷ and Jill P. Buyon³, ¹Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY, ²New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY, ⁴Rheumatology, New York University School of Medicine, New York, NY, ⁵Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY
Background/Purpose: Although hydroxychloroquine (HCQ) is a mainstay of treatment for patients with Systemic Lupus Erythematosus (SLE), ocular toxicity can result from accumulated exposure. The introduction…
Abstract Number: 2892 • 2017 ACR/ARHP Annual Meeting
Persistently Frequent Emergency Department (ED) Utilization Among Systemic Lupus Erythematosus (SLE) Patients
Jiha Lee¹, Lisa Gale Suter^1,2 and Liana Fraenkel^1,3, ¹Rheumatology, Rheumatology, Yale University School of Medicine, New Haven, CT, New Haven, CT, ²Medicine, Rheumatol., TAC S541, Rheumatology, VA Connecticut Healthcare System, West Haven, CT, New Haven, CT, ³Medicine, Section of Rheumatology, Rheumatology, VA Connecticut Healthcare System, West Haven, CT, New Haven, CT
Background/Purpose: SLE patients frequently utilize the ED irrespective of their access to care, which raises concern for inadequate quality of care in the outpatient setting.…
Abstract Number: 669 • 2017 ACR/ARHP Annual Meeting
Unbiased Screening of Urinary Protein Biomarkers for Glomerular Filtration Rate Normalization
Sanam Soomro¹, Samantha Stanley², Ramesh Saxena³, Michelle Petri⁴ and Chandra Mohan¹, ¹Biomedical Engineering, University of Houston, Houston, TX, ²Biomedical Engineering Department, University of Houston, Houston, TX, ³Internal Medicine/Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: To account for glomerular filtration rate, urinary creatinine is routinely used for the normalization of urine biomarkers related to disease. Because of the small…
Abstract Number: 1272 • 2017 ACR/ARHP Annual Meeting
Cluster Analysis of Autoantibodies and Their Relationship with Demographic and Clinical Features in Pediatric Systemic Lupus Erythematosus in the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry
Ginger Janow¹, Uptej Khalsa² and Tracy Andrews³, ¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health Network, Hackensack, NJ, ²Pediatrics, Newark Beth Israel Medical Center, Children's Hospital of New Jersey, Newark, NJ, ³Research, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, heterogeneous, multisystem autoimmune disease characterized, in part, by the presence of autoantibodies. The spectrum of disease presents…
Abstract Number: 1675 • 2017 ACR/ARHP Annual Meeting
SLE Comprises Four Immune-Phenotypes, Which Differ Regarding HLA-DRB1 and Clinical Associations
Lina Marcela Diaz Gallo¹, Emeli Lundström¹, Vilija Oke¹, Kerstin Elvin², Yee Ling Wu³, Johanna Gustafsson¹, Andreas Jönsen⁴, Dag Leonard⁵, Agneta Zickert⁶, Gunnel Nordmark⁷, Anders A. Bengtsson⁴, Johanna K Sandling⁷, Lars Rönnblom⁸, Iva Gunnarsson¹, CHACK-YUNG Yu⁹, Leonid Padyukov¹⁰ and Elisabet Svenungsson¹⁰, ¹Department of Medicine, Rheumatology Unit, Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Dept. of Clinical Immunology and Transfusion Medicine, Unit of Clinical Immunology, Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ³The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, ⁴Lund University, Department of Clinical Sciences, Rheumatology, Lund, Sweden, ⁵Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden, ⁶Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁷Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ⁸Medical Sciences, Rheumatology clinic, Uppsala, Sweden, ⁹Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital, Columbus, OH, ¹⁰Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: SLE is a remarkably heterogeneous disease including diverging clinical symptoms, autoantibodies and genetic susceptibility. Hitherto unrecognized patterns may define sub-phenotypes with different pathogenesis and…
Abstract Number: 2583 • 2017 ACR/ARHP Annual Meeting
Effects of Mycophenolate Mofetil (MMF) on Immunogenicity of Ppsv-23 Vaccine in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases
Priya Prakash¹, Mark Tratenberg², Slavica Bobic³, Rui Zhang⁴, Kirk Sperber⁵, Amy Wasserman⁶ and Julia Ash⁷, ¹Medicine-Rheumatology, New York Medical College / Westchester Medical Center, Valhalla, NY, ²New York Medical College / Westchester Medical Center, valhalla, NY, ³Medicine-Rheumatology, New York Medical College / Westchester Medical Center, valhalla, NY, ⁴Medicine -Rheumatology, New York Medical College / Westchester Medical Center, valhalla, NY, ⁵New York Medical College / Westchester Medical Center, Valhalla, NY, ⁶Medicine - Rheumatology, New York Medical College / Westchester Medical Center, VALHALLA, NY, ⁷Medicine -Rheumatology, New York Medical College / Westchester Medical Center, Valhalla, NY
Background/Purpose: MMF suppresses immune function by inhibiting T cell dependent and independent humoral immune responses. This study investigates the humoral immune response to the PPSV23…
Abstract Number: 2920 • 2017 ACR/ARHP Annual Meeting
Comparative Rates of Osteoporotic Fractures Among U.S. Medicaid Enrollees with and without Systemic Lupus Erythematosus
Sara K. Tedeschi¹, Beatrice Pan¹, Hongshu Guan¹, Seoyoung C. Kim², Daniel H. Solomon¹ and Karen H. Costenbader¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Fractures are potentially avoidable and highly morbid. We studied non-vertebral fracture rates among SLE patients enrolled in Medicaid, the U.S. health insurance program for…
Abstract Number: 676 • 2017 ACR/ARHP Annual Meeting
Immunosignature Autoantibody Profiles Provide Mechanistic Insight into Systemic Lupus Erythematosus and Differentiation from Symptomatically Overlapping Diseases
Theodore M. Tarasow¹, Robert Gerwien¹, Jonathan Melnick¹, Scott A. Melville¹ and Chaim Putterman², ¹HealthTell, Inc., San Ramon, CA, ²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Diagnosis and monitoring of patients with SLE usually requires careful evaluation by a rheumatologist. However, difficulties in accurately quantifing disease and treatment response can…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].